Advertisements



Will the FDA Shoot Down Eli Lilly and Incyte Again?

Incyte and Eli Lilly will be under the microscope next week as the FDA will decide the fate of their rheumatoid arthritis treatment......»»

Category: blogSource: 247wallstApr 20th, 2018

Eli Lilly, Incyte announce results from BRAVE-AA1 trial

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 20th, 2021

Eli Lilly, Incyte announce baricitinib study did not meet primary endpoint

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 8th, 2021

Eli Lilly and Incyte say Phase 3 study of baricitinib in hospitalized COVID-19 patients failed to meet main goal

Eli Lilly & Co. and Incyte Corp. said Thursday a Phase 3 trial of rheumatoid arthritis treatment .....»»

Category: topSource: marketwatchApr 8th, 2021

Eli Lilly, Incyte announce FDA extension of baricitinib sNDA review period

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 6th, 2021

Eli Lilly, Incyte announce BRAVE-AA2 study met primary endpoint

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 3rd, 2021

Eli Lilly, Incyte receive breakthrough therapy designation for baricitinib

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 16th, 2020

Eli Lilly, Incyte announce results from Phase 3 BREEZE-AD5 study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 30th, 2020

Eli Lilly, Incyte announce baricitinib meets primary endpoint in BREEZE-AD4

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 27th, 2020

Eli Lilly, Incyte announce baricitinib meets primary endpoint in Phase 3 trial

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 23rd, 2019

Top Analyst Upgrades and Downgrades: Apple, Chipotle, CEMEX, CVS, Eli Lilly, Hewlett Packard Enterprise, IBM, Incyte, MercadoLibre, US Steel and More

The top analyst upgrades, downgrades and initiations seen on Thursday included Apple, Chipotle Mexican Grill, CEMEX, CVS, Eli Lilly, Hewlett Packard Enterprise, IBM, Incyte, MercadoLibre and U.S.........»»

Category: blogSource: 247wallstApr 11th, 2019

Eli Lilly, Incyte shares drop after mixed FDA drug recommendation

Eli Lilly & Co. shares dropped nearly 3% in premarket trade Tuesday after the comp.....»»

Category: topSource: marketwatchApr 24th, 2018

Biotech Analysis Central Pharma News: Orexigen"s Last Resort, Epizyme"s Partial Clinical Hold, Eli Lilly And Incyte"s Mixed Advisory Panel Vote

Biotech Analysis Central Pharma News: Orexigen"s Last Resort, Epizyme"s Partial Clinical Hold, Eli Lilly And Incyte"s Mixed Advisory Panel Vote.....»»

Category: topSource: seekingalphaApr 24th, 2018

Biotech Analysis Central Pharma News: Biogen"s Deal, Eli Lilly Partner Incyte Refile Baricitinib, Argos Loses Out

Biotech Analysis Central Pharma News: Biogen"s Deal, Eli Lilly Partner Incyte Refile Baricitinib, Argos Loses Out.....»»

Category: topSource: seekingalphaApr 23rd, 2018

Gilead shares drop on FDA concerns with similar Eli Lilly, Incyte drug

Gilead Sciences Inc. shares dropped 2.1% in moderate Thursday trade after a Food .....»»

Category: topSource: marketwatchApr 19th, 2018

Gilead shares drop 2% on FDA concerns with similar Eli Lilly, Incyte drug

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchApr 19th, 2018

Eli Lilly, Incyte shares fall after FDA cites issues with rheumatoid arthritis drug

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchApr 19th, 2018

FDA posting indicates approval granted to Incyte and Eli Lilly"s Baricitinib 2mg

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 1st, 2018

Eli Lilly, Incyte confirm FDA approval of Olumiant

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 1st, 2018

Eli Lilly"s Olumiant Gets FDA Nod for Rheumatoid Arthritis

Eli Lilly (LLY) and its partner Incyte announce approval of their arthritis drug, Olumiant, in the United States. The drug will be available at two-fifth of the price of leading RA drugs. .....»»

Category: dealsSource: nytJun 4th, 2018

Eli Lilly, Incyte shares updated safety analysis of Olumiant in active RA

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 21st, 2018